News Focus
News Focus
Followers 8
Posts 926
Boards Moderated 0
Alias Born 10/01/2020

Re: georgejjl post# 494176

Thursday, 07/17/2025 11:30:24 PM

Thursday, July 17, 2025 11:30:24 PM

Post# of 518862
Sorry, I stand corrected.

ATTENTION-AD will be conducted in parallel with the Phase 2b/3 ANAVEX®2-73-AD-004 study.

All patients who participate in the Phase 2b/3 ANAVEX®2-73-AD-004 study will be eligible to participate also in the ATTENTION-AD study under a voluntary open label extension protocol.

“This is an important development as the patients who have completed the main study, ANAVEX2-73-AD-004, are consistently expressing the wish to gain ongoing access to this investigational therapy” says A/Professor Stephen Macfarlane, FRANZCP, Head of Clinical Services at the Dementia Centre, HammondCare and Principal Investigator for both studies.


Surely Prof. Macfarlane had full access to all data, being the lead investigator?

Dr Marwan is the last name in the journal.

https://www.anavex.com/post/anavex-life-sciences-announces-attention-ad-anavex-2-73-extension-clinical-study-in-early-alzheimer
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News